Company: ARVN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001655759-25-000139
Chunk: 105

Company: ARVINAS, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 105
---
) (*)15.1 25.1 39.2 44.1 ARV-1023.8 1.7 10.3 3.0 ARV-3932.5 1.7 5.1 2.9 ARV-806 1.7 0.2 2.6 0.3 Bavdegalutamide (ARV-110)0.9 2.5 2.0 4.1 Luxdegalutamide (ARV-766)— 9.5 — 13.2 Other programs0.8 — 2.5 — Non program-specific external expense11.1 13.5 25.0 29.6 Compensation and related personnel expense(including stock-based compensation)28.4 36.3 65.3 74.6 Other research and development expense4.3 3.2 7.4 6.2 Total research and development expense68.6 93.7 159.4 178.0 General and administrative expense25.3 31.3 51.9 55.6 Other segment expense, net (**)0.3 0.1 0.4 0.1 Income tax expense(0.3)0.2 (0.2)0.3 Plus:Interest income, net10.3 13.6 22.0 27.6 Segment net (loss) income$(61.2)$(35.2)$21.7 $(104.6)(*)    Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.(**)    Includes primarily realized foreign exchange gains/ losses.During the three months ended June 30, 2025 and 2024, the Company recognized depreciation and amortization expense of $0.8 million and $1.2 million, respectively. During the six months ended June 30, 2025 and 2024, the Company recognized depreciation and amortization expense of $1.5 million and $2.4 million, respectively.

20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis is